Different medicines, indications and product instructions.
Bottom line: The right choice depends on the diagnosed condition and the exact product. The labels do not support using tesamorelin and semaglutide together, and there is no head-to-head winner. [1–3]
| Tesamorelin | Semaglutide | |
|---|---|---|
| Medicine | Tesamorelin, a growth hormone-releasing factor analog. [1,2] | Semaglutide, a GLP-1 receptor agonist. [3] |
| Indications | Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not general weight-loss management. [1,2] | Wegovy: weight management for eligible populations and cardiovascular risk reduction in specified adults. Injection also has accelerated approval for adult noncirrhotic MASH with F2–F3 fibrosis. [3] |
| Formulations | Egrifta WR and SV have different doses, diluents and handling instructions; they are not substitutable. [1,2] | The January 2026 Wegovy label includes weekly injection and daily tablets, with different instructions and eligibility. [3] |
| Comparing results | Abdominal-fat outcomes in HIV lipodystrophy do not predict a general weight-loss result. | Weight-loss percentages cannot be directly compared with percentages of visceral-fat reduction. |
tierA: {"tier":3,"label":"Product-specific approved indication"}
tierB: {"tier":3,"label":"Product-specific approved indications"}
summary: Egrifta labels concern excess abdominal fat in adults with HIV-associated lipodystrophy. The cited Wegovy label covers weight management and additional indications; it is not a generic label for every semaglutide product. [1–3]
trials: []
Yes. The cited Wegovy injection label includes an accelerated-approval indication for adults with noncirrhotic MASH and F2–F3 fibrosis. This is not a blanket indication for all fatty liver disease or every semaglutide product. [3]
The labels cited here do not establish a combined regimen, benefit or safety profile. A mechanistic rationale is not a clinical trial of the combination.
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
